Parkinson's Foundation Expert Briefings offer first-hand access to the latest Parkinson's disease (PD) research and updates from experts in the field. Designed with the Parkinson’s community in mind, each hour-long webinar offers an opportunity to learn more about managing PD symptoms, progression, treatments and more.
Expert Briefings are not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content and information presented in webinars is for general information purposes only. Expert Briefings express the views of the speaker, not necessarily the views of the Parkinson’s Foundation.
Upcoming Expert Briefings
Register for all 2021-2022 Expert Briefing Series by clicking here.
December 1, 2021: The Skinny on Skin and Bone Health in Parkinson's
As Parkinson’s disease (PD) progresses, it is common to experience changes in skin and bone health. Weakened skeletal and bone health can increase risk of falls and balance issues. Changes in the skin or trouble with excessive sweating are also common symptoms of PD. Recent studies have shown an increased prevalence of skin cancer among people with PD. Learn about these changes and how to address them.
February 2, 2022: Sights, Sounds and Parkinson's
As we grow older, it is normal to experience age-related vision and hearing changes. However, for people with Parkinson’s disease (PD), difficulties related to the eyes and vision as well as hearing loss often progress alongside other PD symptoms. Learn more about how changes in vision, hearing as well as other senses including taste and smell impact people with Parkinson’s and how to cope with these changes.
March 2, 2022: Conversations about Complementary Therapies and PD
People with Parkinson’s disease (PD) who seek relief from movement and non-movement symptoms may decide to explore complementary therapies that can support more traditional treatments. There are many kinds of therapies — from mind-body applications or acupuncture to herbal supplements — that may help maximize quality of life. Learn more about how to communicate the use of these therapies with your care providers for optimal outcomes.
April 6, 2022: Can We Put the Brakes on PD Progression?
Discovering the right treatments, interventions and support can enhance your quality of life with Parkinson’s disease (PD), but can it slow progression? Learn what the latest research is saying about slowing Parkinson’s progression including the most promising treatment and day-to-day adjustments. This program will also review how care and treatment strategies are adapted based on lessons learned from the Parkinson’s community.
Previous Expert Briefings
September 1, 2021: The Parkinson’s Journey: Understanding Progression
October 6, 2021: PD & Medication - What's New
Expert Briefings FAQ
What are Expert Briefings?
Expert Briefings are hour-long webinars that give practical tips for managing Parkinson's disease (PD) from experts in the field. Each Expert Briefing has two components: a live presentation followed by a Question and Answer session, where experts answer questions from our virtual audience.
What topics do Expert Briefings cover? How are topics selected?
The Parkinson's Foundation surveys the Parkinson's community and uses feedback to determine which critical issues we cover. Webinars cover wide-ranging topics including coping strategies for movement and non-movement symptoms, caregiving, treatments and research updates.
For our full list of FAQs, click here.
Who should I contact if I have more questions?
For questions regarding Expert Briefings: Email ExpertBriefings@parkinson.org
For Parkinson's disease information and resources: Contact the Parkinson's Foundation Helpline at 1-800-4PD-INFO (1-800-473-4636) or Helpline@Parkinson.org.
For questions about using the Zoom platform: Contact Zoom here.
Phone dial-in for technical issues, contact Zoom in the U.S. at 1.888.799.9666 ext 2 or 1.650.397.6096 ext 2 +Meeting ID
- You can review how to access Zoom at Parkinson.org/Zoom
Supported by a grant from Genentech, a member of the Roche Group: